Chronic Kidney Disease (CKD) is a silent threat that affects millions of people around the world, including in Sub-Saharan Africa. For people living with type 2 diabetes, the potential risks are particularly high unless it’s diagnosed early and treated accordingly.
Up to 40% of people with type 2 diabetes are at risk of developing CKD. This condition often goes unnoticed until it reaches an advanced stage, where individuals may need dialysis and a kidney transplant or face serious heart problems.
In South Africa alone, studies show that more than 10% of the population is already affected by CKD, with similar patterns emerging broadly across Sub-Saharan Africa. Globally, approximately 537 million adults aged 20-79 have diabetes, with around 90% having type 2 diabetes.
Kidneys act as the body’s natural filters, removing waste and regulating fluid balance.
“But in people with type 2 diabetes, high blood sugar levels can gradually damage the small blood vessels that keep the kidneys functioning,” says Dr. Asafika Mbangata, Medical Lead, Cardiovascular/Renal Sub-Saharan Africa at Bayer.
“Over time, this damage causes the kidneys to lose their ability to filter properly. One early warning sign is the leakage of protein into the urine, something health professionals can detect through routine tests. There is, however, hope as Bayer steps up efforts to address the condition through research and medicine innovation, alongside other key stakeholders.
As research advances, experts believe CKD does not need to remain a “silent killer.”
With earlier detection, effective treatment, and greater awareness, patients across the Sub-Saharan Africa region can take control of their health and avoid the most severe complications. As a pioneer and leader in cardiology, Bayer is expanding its portfolio of treatments for cardiovascular and kidney diseases, with several products already in clinical development.
The company’s long-term aim is to transform its cardiovascular portfolio into precision cardiology, addressing unmet medical needs and driving innovation in the field. While leaders in the pharmaceutical space have a significant role to play in assisting those impacted, individuals also have a pivotal role to play.
Doctors recommend four key steps for those living with type 2 diabetes:
- Get tested regularly for kidney health.
- Manage blood pressure and blood sugar levels to reduce strain on the kidneys.
- Discuss treatment options with healthcare providers that go beyond traditional diabetes care.
- Raise awareness in communities to help others act early.
Looking ahead, Dr. Mbangata’s message (alongside that of a range of other health experts) is clear: “All kidneys deserve attention. Early action can save lives. And, as for Bayer’s part, we remain committed to improving access to life-saving medications, promoting health equity, driving pharmaceutical innovation, and forming relevant partnerships, all of which work together to combat complex diseases and enhance patient care throughout Sub-Saharan Africa and beyond.”
